340b Johnson & Johnson Takes the 340B Drug Rebate Fight to Federal Court By medcitynews.com Published On :: Wed, 13 Nov 2024 19:37:54 +0000 Johnson & Johnson is suing the federal agencies overseeing the 340B program that makes discounted medicines more accessible to uninsured and underserved patients. J&J contends the Health Resources Services Administration can’t legally oppose its plan to implement a new rebate plan for certain 340B drugs. The post Johnson & Johnson Takes the 340B Drug Rebate Fight to Federal Court appeared first on MedCity News. Full Article BioPharma Hospitals Legal Pharma 340B drug pricing hospitals HRSA Johnson & Johnson legal
340b ADAP Advocacy Association Launches Ryan White Grantee 340B Project By www.24-7pressrelease.com Published On :: Wed, 16 Nov 2022 08:00:00 GMT Appoints Ryan White Grantee 340B Patient Advisory Committee Full Article
340b Community Access National Network Joins the Alliance to Save America's 340B Program By www.24-7pressrelease.com Published On :: Fri, 24 Mar 2023 08:00:00 GMT ASAP 340B supports true safety-net providers and the communities they serve Full Article
340b ADAP Advocacy Shines Spotlight on 340B Covered Entities Executive Comp By www.24-7pressrelease.com Published On :: Wed, 14 Aug 2024 08:00:00 GMT The 340B Drug Pricing Program and its Potential Impacts on Annual Revenues, Executive Compensation, and Charity Care Provision in Eligible Covered Entities Full Article
340b ADAP Advocacy Association Joins Alliance to Save America's 340B Program By www.24-7pressrelease.com Published On :: Tue, 28 Mar 2023 08:00:00 GMT Alliance reinforces the urgency for action today to ensure the long-term viability of the program for tomorrow Full Article
340b Community Access National Network Launches "340B What About Me?" Campaign By www.24-7pressrelease.com Published On :: Mon, 29 Jan 2024 08:00:00 GMT Bad actors are exploiting the federal drug discount program to the detriment of patients – it's time for policymakers to listen to us. Full Article
340b Hospitals Are Relying More on PBMs to Manage Manufacturers' 340B Contract Pharmacy Restrictions: DCI's 2024 Market Analysis (rerun) By feeds.feedblitz.com Published On :: Wed, 02 Oct 2024 10:30:00 +0000 This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from June 2024. The 340B contract pharmacy market shows little sign of slowing down. Drug Channels Institute’s exclusive analysis of the 2024 market reveals that:About 33,000 pharmacy locations—more than half of the entire U.S. pharmacy industry—act as contract pharmacies for the hospitals and federal grantees that participate in the 340B program. Five multi-billion-dollar, for-profit, publicly traded pharmacy chains and pharmacy benefit managers (PBMs)—Cigna (via Express Scripts), CVS Health, UnitedHealth Group (via OptumRx), and Walgreens, Walmart—continue to dominate the 340B contract pharmacy market.Federal grantees are aligned primarily with the vertically intergated organizations' retail pharmacies, while hospitals rely on mail and specialty pharmacies.Over the past four years, manufacturers’ restrictions on 340B contract pharmacies have led hospitals to deepen their relationships with the largest PBMs—even as those PBMs have simultaneously limited hospitals’ direct participation in specialty pharmacy networks. For an updated look at what’s next for the 340B contract pharmacy market, join Adam J. Fein, Ph.D., on June 21 for his latest live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook. Read more » Full Article 340B Channel Management Hospitals Inflation Reduction Act of 2022 Pharmacy Specialty Drugs
340b The 340B Program Reached $66 Billion in 2023—Up 23% vs. 2022: Analyzing the Numbers and HRSA’s Curious Actions By feeds.feedblitz.com Published On :: Tue, 22 Oct 2024 10:30:00 +0000 Reality has again failed to support the spin surrounding the 340B Drug Pricing Program. For 2023, discounted purchases under the 340B program reached a record $66.3 billion—an astounding $12.6 billion (+23.4%) higher than its 2022 counterpart. The gross-to-net difference between list prices and discounted 340B purchases also grew, to $57.8 billion (+$5.5 billion). 340B purchases are now almost 40% larger than Medicaid’s prescription drug purchases. Hospitals again accounted for 87% of 340B purchases for 2023. Purchases at every 340B covered entity type grew, despite drug prices that grew more slowly than overall inflation. Lobbyists claim that manufacturers’ 340B contract pharmacy changes are “stripping billions of dollars from the healthcare safety net.” But every year, the data tell a very different story. Only in the U.S. healthcare system can billions more in payments and spreads be considered a cut. Read on for full details and our analysis, along with fresh details of troubling behavior by the Health Resources and Services Administration (HRSA). Read more » Full Article 340B Channel Management Gross-to-Net Bubble Hospitals Inflation Reduction Act of 2022 PBMs Pharmacy Specialty Drugs
340b Community Access National Network Tackles Challenges Facing the 340B Drug Pricing Program By www.24-7pressrelease.com Published On :: Wed, 18 Apr 2018 07:00:00 GMT Launches National Commission to Make Recommendations to Congress Full Article
